ConSynance Therapeutics

Executive Summary

ConSynance Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies for rare central nervous system (CNS) disorders. Founded in 2021 and headquartered in Cambridge, MA, the company leverages its proprietary 'tunable' triple monoamine reuptake inhibitor platform to address high unmet medical needs in neuropsychiatric conditions linked to dysregulation of serotonin, dopamine, and norepinephrine. By precisely modulating these neurotransmitters, ConSynance aims to provide improved efficacy and tolerability compared to existing treatments. The company's lead program targets Prader-Willi Syndrome (PWS), a rare genetic disorder characterized by hyperphagia, behavioral issues, and metabolic dysfunction, for which there are no approved therapies targeting the underlying neurobiology. ConSynance is currently advancing its lead candidate through Phase 1 clinical trials, with initial safety and pharmacokinetic data expected in the near term. The company's platform also holds potential for expansion into other CNS indications, such as depression and anxiety disorders, where triple reuptake inhibition may offer advantages. As a private company, ConSynance is well-positioned to attract strategic partnerships or additional financing based on clinical progress. The management team brings deep experience in CNS drug development, and the company's focused pipeline addresses a clear orphan disease opportunity with regulatory incentives. While still early-stage, ConSynance's innovative approach and clear value proposition warrant attention from investors seeking exposure to rare disease therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 top-line safety and PK data for lead candidate in Prader-Willi Syndrome70% success
• Q2 2027FDA feedback on Phase 2 trial design for lead program80% success
• H1 2027Announcement of strategic partnership or licensing deal for platform technology40% success